Zevra Therapeutics is trading at $11.80, up 6.50% pre-market, with no clear catalyst identified. - No company-specific announcement dated October 8 was identified; the latest listed release, on October 2, covered four-year MIPLYFFA real-world data. - The rise comes despite weaker futures and broad-market caution; major U.S. indices were down less than 0.5%, offering no strong same-direction explanation. - Recent coverage and company updates identify no overnight earnings, regulatory, or other major company event explaining the move.